• Explore /
  • Poster
  • / A phase II study of savolitinib (volitinib, AZD6094, HMPL-504) in subjects with <em>MET</em> amplified metastatic colorectal cancer (mCRC) detected by cell-free (cf)DNA.

A phase II study of savolitinib (volitinib, AZD6094, HMPL-504) in subjects with MET amplified metastatic colorectal cancer (mCRC) detected by cell-free (cf)DNA.

Abstract Poster

Authors

null

Jingquan Jia

DUMC, Department of Medical Oncology, Durham, NC

Jingquan Jia , Donna Niedzwiecki , Christy Arrowood , Nancy Garett-Mead , Rebecca Nagy , Richard B. Lanman , John Wright , Andrew B. Nixon , John H. Strickler

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session C: Anal and Colorectal Cancer

Track

Colorectal Cancer,Anal Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03592641

Citation

J Clin Oncol 38, 2020 (suppl 4; abstr TPS270)

Abstract #

TPS270

Poster Bd #

N4

Abstract Disclosures

Similar Posters

First Author: John H. Strickler

First Author: John H. Strickler

First Author: Samuel A. Jacobs

First Author: Stefania Napolitano